Clinical experience with infliximab for Crohn’s disease: RESULTS Part 1

3 May

Patient characteristics

A total of 109 patients, 57 men and 52 women treated by 13 gastroenterologists, were included in the study. The median age was 42.5 years (range 18 to 79 years). Patient demographic characteristics, including previous and current medical and surgical therapy, and concomitant medical treatment are summarized in Table 1. Indications for infliximab therapy were inflammatory Crohn’s disease (54 patients [50%]), Crohn’s fistulae (38 patients [35%]), and both inflammatory and fistulizing Crohn’s disease (17 patients [16%]). The median follow-up was 24 weeks (range six to 88 weeks). Efficient treatment has got less costly: find at best online pharmacy.

Demographics and characteristics of patients with inflammatory and/or fistulizing Crohn’s disease who were treated with infusions of infliximab

Mean age, years (range)39.2 (18-79)
Mean duration of disease, years (range)12.4 (1-31)
Extraintestinal manifestations (n)11/109
Previous total parenteral nutrition therapy (n)8/109
Previous surgery for Crohn’s disease (n)75/109
Disease distribution
Small bowel only (n)25/109
Colon only (n)14/109
Small bowel and colon (n)70/109
Indication for infliximab
Inflammatory only (n)54/109
Fistulae only (n)38/109
Inflammatory and fistulae (n)17/109
Previous medications
Mesalamine (n)93/109
Methotrexate (n)28/109
6-Mercaptopurine (n)6/109
Azathioprine (n)76/109
Cyclosporine (n)16/109
Corticosteroids (n)103/109

Treatment with infliximab

Patients received between one and nine infusions of infliximab 5 mg/kg. Patients with fistulizing disease received three doses of infliximab over six weeks as induction therapy. Forty-three of the 80 patients who initially responded were retreated with additional doses of infliximab for maintenance of remission. The majority of infliximab infusions (98%) were administered in an outpatient setting.